Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones
Completado reclutamiento de pacientes
Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany, Completes Target Enrollment in the TH-302 Phase 3 MAESTRO Study in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/03/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today announced that Threshold's partner Merck KGaA, Darmstadt, Germany, through its biopharmaceutical division, has completed target enrollment of 660 patients in the global Phase 3 MAESTRO
«Después de nada, o después de todo/ supe que todo no era más que nada.»